Reply for the following discussion. at least 150 words, 2 references, APA style, Turnitin less than 10 % and 0% AI. 

New pharmacological treatments have been developed in response to the prevalence of obesity and type 2 diabetic mellitus (T2DM). Ozempic (semaglutide) and Mounjaro (tirzepatide) have become important treatment choices among them. (Watanabe at el, 2024).

An estimated $92 billion is spent on healthcare each year in the United States due to overweight and obesity, and adults who are obese have an additional $2505 in medical expenses annually, which are mostly related to morbidity and mortality from cardiovascular disease (CVD). Minorities are disproportionately affected by obesity, with non-Hispanic Black adults (34.9%) and Hispanic adults (44.8%) having the greatest rates.2. Obesity is made more complex from a health equity perspective since racial and ethnic minorities are linked to worse weight loss treatment response to behavioral, pharmaceutical, and surgical therapies.5. The FDA has approved several glucagon-like peptide 1 (GLP-1) receptor agonists that have been associated with significant weight loss, which has sparked interest in demand and cost estimates. (Person at el., 2023)

Being glucagon-like peptide-1 receptor agonists (GLP-1 RAs), Mounjaro and Ozempic increase insulin secretion, postpone stomach emptying, and decrease hunger. Since tirzepatide (Mounjaro) is a dual agonist, it can potentially increase metabolic effects beyond those of semaglutide (Ozempic), which only targets GLP-1 receptors. It does this by targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. (Watanabe at el, 2024)

Tirzepatide may provide better results in weight loss and glycemic control than semaglutide, according to recent research. Patients on tirzepatide had a 1.8-fold higher chance of losing at least 5% of their body weight, a 2.5-fold higher chance of losing 10%, and a 3.2-fold higher chance of losing 15% of their body weight, according to cohort research conducted on individuals who were overweight or obese. Additionally, tirzepatide significantly increased the average reductions in body weight at 3, 6, and 12 months. (Rodriguez at el, 2024)

Similarly, a randomized clinical trial reported that tirzepatide achieved greater reductions in hemoglobin A1c levels and body weight than semaglutide. The dual agonist activity of tirzepatide is hypothesized to contribute to these enhanced effects. (Frias at el, 20221)

Common side effects of these drugs are mostly gastrointestinal in nature and include nausea, vomiting, and diarrhea. Between the two medications, the frequency of these adverse effects seems to be similar. Concerns have been raised recently, nevertheless, regarding possible severe side effects, such as eyesight issues linked to GLP-1 drugs like Ozempic and Mounjaro. There have been reports of non-arteritic anterior ischemic optic neuropathy (NAION), which causes abrupt blindness. Even though they are uncommon, these occurrences highlight the need for close observation.  (Watanabe at el, 2024)

For individuals with type 2 diabetes and obesity, tirzepatide’s improved effectiveness in weight loss and glycemic management presents a potential alternative. However, when choosing a treatment, factors like cost, patient comorbidities, and possible side effects are very important. For optimal therapy customization, healthcare providers must consider these aspects. The long-term safety characteristics of these drugs must be thoroughly clarified by ongoing research and post-marketing surveillance. (Frias at el, 2021)

The pharmaceutical treatment of type 2 diabetes and obesity has benefited greatly by the development of Mounjaro (tirzepatide) and Ozempic (semaglutide). Despite tirzepatide’s increased effectiveness in recent research, clinical judgments must be based on the unique characteristics of each patient as well as any possible hazards. To maximize therapeutic approaches and guarantee patient safety, more research is necessary. (ADA, 2021)